 |
A
Welcome and Introductory Remarks
Eduardo Slatopolsky, MD, FACP. |
|
Molecular Aspects of Vascular Calcification
Cecilia M. Giachelli, PhD. |
|
Slowing the Progression of Cardiac Calcification
Glenn M. Chertow, MD, MPH. |
|
Non-Invasive Screening for Cardiac Calcification
Paolo Raggi, MD, FACP, FACC. |
|
Panel Discussion
Eduardo Slatopolsky, MD, FACP, and Panel |
After participating
in this activity, participants should be able to:
Characterize the development and consequences of hyperphosphatemia;
Understand how to balance phosphorus and calcium in patients with ESRD;
Recognize the impact of hyperphosphatemia on vascular and cardiac calcification: and
Describe methods and therapies and recognize their clinical significance for hyperphosphatemia.
Glenn M. Chertow, MD, MPH
Associate Professor of Medicine
University of California, San Francisco
School of Medicine
San Francisco, California
Cecilia M. Giachelli, PhD
Associate Professor of Bioengineering
University of Washington
Seattle, Washington
Paolo Raggi, MD, FACP, FACC
Associate Professor of Medicine
Director of Noninvasive and Preventive Cardiology
Tulane University School of Medicine
New Orleans, Louisiana
Eduardo Slatopolsky, MD, FACP
Joseph Friedman Professor of Renal Disease in Medicine
Washington University of St. Louis
St. Louis, Missouri
|
|
 |
|
|
Post-test and evaluation form are at
this link, but you must listen to all talks
from this symposium prior to completing the
test.
|
|
CME: The University of Minnesota is accredited by the Accreditation
Council for Continuing Medical Education (AACME) to sponsor continuing medical education
for physicians.
The
University of Minnesota designates this educational
activity for up to 1.5 hours in category 1 credit
towards the AMA Physician's Recognition Award. Each physician
should claim only those hours of credit actually spent
in the educational activity.
CEU: These talks are also designated to provide 1.5 hours of CEU nursing education credits, sponsored
by the Renal Education Association. The Renal Education Association is accredited by
the State of California Board of Nursing to provide continuing education for nurses
(provider number: CEP 13092).
Posting date: June 27, 2002.
Review date: June 27, 2003 |
|
INSTRUCTIONS FOR CREDIT : |
Participation
in this self-study activity should be completed in approximately
two (1.5) hours. There are no fees for participating and receiving
CME or CEU credit for this activity. To successfully complete this
activity and receive credit, participants must follow these
steps during the period June 27, 2002 through June 27, 2003.
1. Register for continuing education credit by completing the
registration process.
2. Read the goals and learning objectives.
3. Read the article text and tables, and review figures.
4. Read, complete, and submit answers to the post test questions
and evaluation questions. You must receive a test score of at
least 75% and respond to all evaluation questions to receive
your online CME or CEU certificate.
The
primary target audience is physicians involved in the care of renal patients (CME), and nephrology nurses,
dialysis technicians and pharmacists (CEU).
|
FACULTY
DISCLOSURE STATEMENTS : |
All
faculty participating in continuing medical education programs
are expected to disclose to the program audience any real or
apparent conflict of interest related to the subject under discussion.
The faculty disclosure information is as follows:
Glenn M. Chertow, MD, MPH, receives grant support and honoraria from Genzyme Therapeutics and Amgen. He is also a physician advisory board member for Genzyme Therapeutics and
Amgen
Cecilia M. Giachelli, PhD, indicates no relevant affiliations or financial interest or arrangements.
Paolo Raggi, MD, FACP, FACC, receives
grant support and honoraria from Genzyme Therapeutics and is a stockholder in Pfizer Inc. Dr. Raggi’s presentation will include off-label or investigational use of a drug.
Eduardo Slatopolsky, MD, FACP, consults
for Chugai, Abbott Laboratories, and Genzyme Therapeutics. He has received grant support from Geltex and honoraria from Abbott Laboratories and Genzyme Therapeutics. He is also a stockholder in
Merck and Amgen. Dr. Slatopolsky’s presentation will include off-label or investigational use of a drug
|
DISCLOSURE OF UNLABELED USE: |
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by FDA.
The University of Minnesota, ASN, HDCN and the Renal Education Association do not recommend the
use of any agent outside of the labeled indications. Please
refer to the official prescribing information for each product
for discussion of approved indications, contraindications and
warnings.
|
|
